Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Jordan Hospital Merck |
---|---|
Information provided by: | Jordan Hospital |
ClinicalTrials.gov Identifier: | NCT00407771 |
Patients taking part in the study will be assigned by chance into two groups.
All patients will be loaded with 600 mg clopidogrel at least 4 hours prior to scheduled intervention.
All patients will have platelet function analyses at baseline and following treatment.
Condition | Intervention | Phase |
---|---|---|
Coronary Artery Disease |
Drug: Tirofiban |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention |
Estimated Enrollment: | 44 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | December 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Imad A Alhaddad, MD | 0096265626197 | alhaddad@pol.net |
Jordan | |
Jordan Hospital | |
Amman, Jordan, 11152 |
Principal Investigator: | Imad A Alhaddad, MD | Jordan Cardiovascular Center |
Study ID Numbers: | 2006-alhaddad |
Study First Received: | December 1, 2006 |
Last Updated: | October 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00407771 |
Health Authority: | Jordan: Ministry of health |
platelet function assay Glycoprotein inhibitors percutaneous coronary intervention Diabetes Mellitus |
Arterial Occlusive Diseases Coronary Disease Heart Diseases Tirofiban Myocardial Ischemia Vascular Diseases |
Diabetes Mellitus Arteriosclerosis Ischemia PS-K Coronary Artery Disease |
Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents Platelet Aggregation Inhibitors |
Fibrinolytic Agents Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |